China plans to impose a maximum tariff of 25% on US$60 billion of goods (second batch)

Medical Network August 4th, August 3, the State Council Customs Tariff Commission issued an announcement, China will adopt tariff increases measures, decided to impose tariffs on some imported goods (second batch) originating in the United States. On the basis of announcing the list of 10% tariffs on the Chinese side’s 200 billion US dollars exported to the United States, it also proposed to increase the tax rate from 10% to 25%.

According to the "People's Republic of China Foreign Trade Law", "People's Republic of China Import and Export Tariff Regulations" and other laws and regulations and the basic principles of international law, with the approval of the State Council, the State Council Tariff Commission decided to purchase about 60 billion US dollars of goods originating in the United States, about 60 billion US dollars, Add 25%, 20%, 10%, 5% tariffs.

It is worth noting that the implementation date of this taxation measure has not yet been determined. It will depend on the actions of the US side. China reserves the right to continue to introduce other countermeasures.

The reporter of the "Medical Economics News" first sorted out the matter. The State Council Tariff Commission decided to involve more types of pharmaceutical products in the 5,207 tax items originating in the United States of about 60 billion US dollars.

The list of tariffed goods with 25% tariffs on the United States involves unmixed vitamin B2 and its derivatives; unmixed D or DL-pantothenic acid and its derivatives; unmixed vitamin B12 and its derivatives; recombinant human insulin and its salts Other insulins and their salts; other peptide hormones, protein hormones, glycoprotein hormones and their derivatives and similar structures; halogenated derivatives of other corticosteroids; halogenated derivatives of other corticosteroids; Hormone and its derivatives and similar structures; prostaglandins, thromboxanes and leukotrienes and their derivatives and structural analogues; other natural or synthetically prepared glycosides and their salts, ethers, esters and other derivatives; And its derivatives and salts; other cephalosporins and their derivatives and their salts; adhesive plasters (drug-coated or retail packaging for medical, surgical, dental or veterinary use); X-ray contrast agents; 1. Diagnostic reagents; chemical contraceptives based on hormones, etc.

The list of 20% tariffs on the United States and Canada involves medical or laboratory disinfection equipment, acetaminophen (paracetamol), unmixed vitamin B6 and its derivatives, unmixed vitamin C and its derivatives.

A list of 10% tariff items on the US, involving fresh, cold, frozen or dried American ginseng, first aid kits, medicine packs, gel products specially designed for human or veterinary use, as lubrication for body parts during surgery or physical examination. Agent, or as a body and medical instruments Between the coupling agent, medical vulcanized rubber clothing and accessories, vulcanized rubber other sanitary and medical supplies, medical vulcanized rubber clothing and accessories, other non-medical X-ray equipment, medical alpha, beta, gamma-ray equipment, other medical , surgical or veterinary furniture and parts.

In the list of 5% tariffs on the United States, it involves o-acetylsalicylic acid (aspirin); other esters of salicylic acid and its salts; procaine; amphetamine, benzethamine, dextroamphetamine, Bifamine, fencamfamamine, rifampicin, levofloxacin, mefenex, phentermine and their salts; alfentanil, anilidine, cyanamide, bromozinidine, Difenofin, diphenoxylate, dipyridone, fentanyl, ketomizate, methylphenidate, pentazin, pethidine, meperidine intermediate A, phencyclidine, Phenylpiperidine, piperoxyn, piperacipamide, propidium and trimethylpyridin and their salts; alprazolam, carbamazepine, etc. and their salts; amirex, bromozolam, chlorine Thioxacene and the like; other antibiotics; other natural or synthetically reconstituted hormones and their derivatives and structural analogues, including modified chain polypeptides mainly used as hormones; other ampicillin salts; streptomycin and Derivatives, and their salts; other adhesive dressings and articles with adhesive coatings (drug-coated or retail packaging for medical, surgical, dental or veterinary use); cotton wool, yarn , bandages (drug-coated or manufactured; retail packaging for medical, surgical, dental or veterinary use); other medical soft fillers and similar articles (medicated, surgical, dental or veterinary) Sterile surgical gut; sterile kelp, sterile adhesive tape, sterile absorbent hemostatic material, surgical or dental sterile anti-adhesive barrier material and similar sterile material blood type reagent.

It is proposed to increase the tax rate of the Chinese 200 billion US dollars to the US products from 10% to 25%.

On July 11, the US government issued measures to impose a 10% tariff on imports of about 200 billion US dollars from China. On August 2, the US Trade Representative stated that it intends to increase the tax rate from 10% to 25%.

The results of the US Trade Representative Office's consultation on the additional tariff list of US$200 billion in China's exports to the US are expected to be announced around August 30. The reporter noted that from the previously disclosed situation, the target product list is intended to involve food. Dietary supplements, etc. When the list becomes effective, the results of the consultation are still pending.

CoQ10, which was previously widely concerned by the industry, was initially included in the first tariff list, but was eventually cancelled and not included in the newly proposed tariff list. According to the latest combing of the planting bridge, the second proposed tax increase list Contains raw materials commonly used in the food and dietary supplement industry, including cod liver oil; xylitol, sucrose and beet sugar; large amounts of minerals (calcium, sodium, potassium, zinc, magnesium); phospholipids; choline; other herbs and plants (seaweed , ephedra, ginseng); in addition to oatmeal, corn, buckwheat and rice; inulin; various vegetables (soybeans, carrots, peas, chickpeas, etc.); various fruits (mangosteen, guava, strawberry, banana , coconut, etc.; a variety of nuts (peanuts, almonds, walnuts, chestnuts, pistachios), etc.

Because the United States is China Healthy food The largest exporter, the export volume is twice that of the second Hong Kong, China. Moreover, some health food exports are re-exported to the United States through Hong Kong, China, etc., so the proportion of health food actually exported to the United States may be higher. If the United States implements a list to increase import tariffs on domestically produced varieties, it will have a certain impact on the export of Chinese health food.

In the interview, a concern of Beijing Health care products A senior person in import and export told the reporter of the Pharmaceutical Economics News, 'The United States is one of the most important markets for Chinese medicine and health care products, increasing tariffs by 10% to 25%. Currently, for the nutrition and health food products, several exports A large amount of tax code is not included in the list, personal feelings still have an impact, but may not be too big.

Although from the current point of view, if the high import tariff on Chinese products is raised from 10% to 25%, the export of Chinese medicine and health food will have a certain impact in the short to medium term, but some experts believe that the medical and health food industry is not in the middle. At the core of the US trade dispute, the core of the US trade dispute against China is the monopolistic industries in the state-owned enterprises, such as steel and aluminum. Therefore, the complex and diverse health food products will not become the 'main battlefield', even if it is affected, The impact is also extremely limited.

On the one hand, China does not have much preparation products exported to the United States. On the other hand, although the United States is the world's largest single market, the export of China's medical and health care industry has been diversified, and the market in other countries has been developing. Authoritative experts said.

'The list is currently based on raw materials, and the finished products of health foods are not much covered.' The seniors in the health care products mentioned above told this reporter that 'coenzyme Q10 was in the list before, but it did have a great impact on the US market because of the price. Rising, many factories stopped producing coenzyme Q10 products, which were later removed from the list. Whether it is in the list or not, the key is to look at alternatives.

For the increase of tariffs, industry analysts also put forward feasible suggestions for enterprises. An industry source reminded that 'pharmaceutical enterprises that account for a relatively large export to the US should focus on risks. It is necessary to prepare the plan in advance and minimize the risk zone. At the same time, strengthening its own quality and innovation ability is the core. In addition, domestic enterprises should expand domestic demand in the Chinese market, and increase the trade quota of other countries and regions.

The reporter noted that in recent years, with the continuous improvement of people's living standards and the rapid growth of national purchasing power, China's per capita health care expenditure has also increased rapidly. In 2016, it grew to 1,307 yuan, with a compound annual growth rate of 12.74%. The domestic market demand is strong.

In terms of foreign trade, China actively expands its 'export business to other countries in Europe and Asia under the core strategy of China's Belt and Road. The relevant person in charge of the Foreign Trade Department of the Ministry of Commerce of China revealed in Beijing on July 17 that in the first half of this year, China All the way to the emerging markets such as countries along the BRIC countries and imports and exports to maintain rapid growth. China's exports to the United States, the European Union, Hong Kong and other traditional markets increased by 5.7%, 4.0% and 5.8% respectively; for some countries along the 'Belt and Road' and gold Imports and exports of emerging markets such as brick countries maintained rapid growth, with imports and exports to Vietnam, Indonesia, Russia and Brazil reaching 19.8%, 18.8%, 16.0% and 15.4% respectively.